BNP and NT-proBNP are widely used biomarkers of heart failure. However, obesity influences the concentrations of these markers in circulation, and unfortunately the underlying reasons for this are not well understood. In practice it currently means that the clinical utility of these biomarkers is limited if the patient is obese. Now Lewis et al. have addressed this understudied topic related to interrelationship between obesity and BNP/NT-proBNP.
Read the editorial and listen to the accompanying podcast for an interview with Dr. Semenov.